That might sound fuzzy, but over a decade, it’s a useful hypothesis: How would an ecosystem-led investment fund perform?
The RealLIST portfolio has shifted dramatically over time. The earliest, pre-pandemic cohorts were overwhelmingly SaaS, close to 95% of the first three classes. Last year, just 4 in 5 were.
The difference is largely hardware, robotics and life sciences companies — sectors that reflect the research strengths of regional ecosystems like Pittsburgh’s robotics community, the DC metro’s national defense, Maryland’s health and Philadelphia’s life sciences clusters.
Interestingly, those companies also appear to exit at nearly twice the rate of purely software companies in the dataset. That shift may not be accidental. Deep-tech companies are harder to start, but when they succeed they are often acquired by large strategic buyers looking for specialized technology.
Most startups don’t leave their hometowns
Another persistent startup myth is that any company that becomes successful eventually moves to Silicon Valley. The RealLIST data suggests something different.
More than 90% of the startups we selected are still headquartered in the same city where they started.
No doubt there’s likely selection bias: Our newsroom is far more likely to know an entrepreneur who is invested in where they live. Still, that doesn’t mean companies never relocate — some certainly do — but the narrative that regional startups inevitably migrate west appears overstated.
For founders building companies tied to local universities, hospitals or industry clusters, staying put often makes sense. Startups grow where early customers cluster.
Healthcare and biotech companies represent only about 10% of the RealLIST portfolio, yet they likely account for more than half of the exit value.
The most obvious example is Spark Therapeutics, the Philadelphia gene-therapy company acquired by Roche for $4.3 billion, the largest reported exit in the dataset by an order of magnitude. Then still-young, Spark was named to our inaugural RealLIST, though they’ve since struggled as a division.
A steady stream of healthcare startups across the Mid-Atlantic has produced acquisitions by major pharmaceutical, diagnostics and medical device companies.
In other words, the region’s hospital and university research infrastructure continues to generate companies that strategic buyers find valuable. A few produced outsized “home run” returns like Spark, but far more were reliable “doubles,” as healthcare investors predict
Our newsroom portfolio looks a lot like venture capital
Taken together, the results look surprisingly familiar. The RealLIST “portfolio” appears to behave much like the average venture fund:
- A small number of large wins carry the financial outcome
- A modest number of exits produce meaningful returns
- Many companies survive but never reach venture-scale outcomes
That’s not entirely surprising. Journalists selecting companies that appear meaningful in local ecosystems are likely to pick businesses that are credible and durable, even if they are not chasing the hyper-growth trajectory venture investors typically seek.